Immuron (FRA:ANW) Beginning Cash Position : €10.53 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Immuron Beginning Cash Position?

Immuron's Beginning Cash Position for the quarter that ended in Dec. 2023 was €10.53 Mil.

Immuron's quarterly Beginning Cash Position declined from Dec. 2022 (€14.08 Mil) to Jun. 2023 (€11.44 Mil) and declined from Jun. 2023 (€11.44 Mil) to Dec. 2023 (€10.53 Mil).

Immuron's annual Beginning Cash Position increased from Jun. 2021 (€2.06 Mil) to Jun. 2022 (€16.65 Mil) but then declined from Jun. 2022 (€16.65 Mil) to Jun. 2023 (€13.70 Mil).

Immuron Beginning Cash Position Historical Data

The historical data trend for Immuron's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Beginning Cash Position Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Beginning Cash Position

Get a 7-Day Free Trial

2.91

3.14

2.06

16.65

13.70

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial												15.86	15.15	14.08	11.44	10.53

Immuron Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Immuron Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Immuron's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines